TMED3 Promotes Proliferation and Migration in Breast Cancer Cells by Activating Wnt/β-Catenin Signaling

References

• Tao Z, Shi A, Lu C, Song T, Zhang Z, Zhao J. Breast cancer: epidemiology and etiology. Cell Biochem Biophys. 2015;72(2):333–338. doi:10.1007/s12013-014-0459-625543329
   PubMed Web of Science ®Google Scholar
• Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–289. doi:10.3322/caac.2134927253694
   PubMed Web of Science ®Google Scholar
• Jenne N, Frey K, Brugger B, Wieland FT. Oligomeric state and stoichiometry of p24 proteins in the early secretory pathway. J Biol Chem. 2002;277(48):46504–46511. doi:10.1074/jbc.M20698920012237308
   PubMed Web of Science ®Google Scholar
• Strating JR, Hafmans TG, Martens GJ. Functional diversity among p24 subfamily members. Biol Cell. 2009;101(4):207–219. doi:10.1042/BC2008007518699773
   PubMed Web of Science ®Google Scholar
• Strating JR, Martens GJ. The p24 family and selective transport processes at the ER-Golgi interface. Biol Cell. 2009;101(9):495–509. doi:10.1042/BC2008023319566487
   PubMed Web of Science ®Google Scholar
• Port F, Hausmann G, Basler K. A genome-wide RNA interference screen uncovers two p24 proteins as regulators of wingless secretion. EMBO Rep. 2011;12(11):1144–1152. doi:10.1038/embor.2011.16521886182
   PubMed Web of Science ®Google Scholar
• Duquet A, Melotti A, Mishra S, et al. A novel genome-wide in vivo screen for metastatic suppressors in human colon cancer identifies the positive WNT-TCF pathway modulators TMED3 and SOX12. EMBO Mol Med. 2014;6(7):882–901. doi:10.15252/emmm.20130379924920608
   PubMed Web of Science ®Google Scholar
• Buechling T, Chaudhary V, Spirohn K, Weiss M, Boutros M. p24 proteins are required for secretion of Wnt ligands. EMBO Rep. 2011;12(12):1265–1272. doi:10.1038/embor.2011.21222094269
   PubMed Web of Science ®Google Scholar
• Li X, Wu Y, Shen C, Belenkaya TY, Ray L, Lin X. Drosophila p24 and Sec22 regulate wingless trafficking in the early secretory pathway. Biochem Biophys Res Commun. 2015;463(4):483–489. doi:10.1016/j.bbrc.2015.04.15126002470
   PubMed Web of Science ®Google Scholar
• Shi-Peng G, Chun-Lin C, Huan W, et al. TMED2 promotes epithelial ovarian cancer growth. Oncotarget. 2017;8(55):94151–94165. doi:10.18632/oncotarget.2159329212217
   PubMedGoogle Scholar
• Seno A, Kasai T, Ikeda M, et al. Characterization of gene expression patterns among artificially developed cancer stem cells using spherical self-organizing map. Cancer Inform. 2016;15:163–178. doi:10.4137/CIN.S3983927559294
   PubMedGoogle Scholar
• Xu X, Gao H, Qin J, He L, Liu W. TMP21 modulates cell growth in papillary thyroid cancer cells by inducing autophagy through activation of the AMPK/mTOR pathway. Int J Clin Exp Pathol. 2015;8(9):10824–10831.26617795
   PubMed Web of Science ®Google Scholar
• Pei J, Zhang J, Yang X, et al. TMED3 promotes cell proliferation and motility in breast cancer and is negatively modulated by miR-188-3p. Cancer Cell Int. 2019;19:75. doi:10.1186/s12935-019-0791-430976199
   PubMed Web of Science ®Google Scholar
• Zheng H, Yang Y, Han J, et al. TMED3 promotes hepatocellular carcinoma progression via IL-11/STAT3 signaling. Sci Rep. 2016;6:37070. doi:10.1038/srep3707027901021
   PubMed Web of Science ®Google Scholar
• Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell. 2012;149(6):1192–1205. doi:10.1016/j.cell.2012.05.01222682243
   PubMed Web of Science ®Google Scholar
• Nusse R, Clevers H. Wnt/beta-catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169(6):985–999. doi:10.1016/j.cell.2017.05.01628575679
   PubMed Web of Science ®Google Scholar
• King TD, Suto MJ, Li Y. The Wnt/beta-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer. J Cell Biochem. 2012;113(1):13–18. doi:10.1002/jcb.2335021898546
   PubMed Web of Science ®Google Scholar
• Dey N, Barwick BG, Moreno CS, et al. Wnt signaling in triple negative breast cancer is associated with metastasis. BMC Cancer. 2013;13:537. doi:10.1186/1471-2407-13-53724209998
   PubMed Web of Science ®Google Scholar
• Ha M, Moon H, Choi D, et al. Prognostic role of TMED3 in clear cell renal cell carcinoma: a retrospective multi-cohort analysis. Front Genet. 2019;10:355. doi:10.3389/fgene.2019.0035531057605
   PubMed Web of Science ®Google Scholar
• Vainio P, Mpindi JP, Kohonen P, et al. High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer. PLoS One. 2012;7(6):e39801. doi:10.1371/journal.pone.003980122761906
   PubMed Web of Science ®Google Scholar
• Roy PG, Thompson AM. Cyclin D1 and breast cancer. Breast. 2006;15(6):718–727. doi:10.1016/j.breast.2006.02.00516675218
   PubMed Web of Science ®Google Scholar
• Loden M, Nielsen NH, Roos G, Emdin SO, Landberg G. Cyclin E dependent kinase activity in human breast cancer in relation to cyclin E, p27 and p21 expression and retinoblastoma protein phosphorylation. Oncogene. 1999;18(16):2557–2566. doi:10.1038/sj.onc.120248810353599
   PubMed Web of Science ®Google Scholar
• Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, Bernards R, Michalides RJ. CDK-independent activation of estrogen receptor by cyclin D1. Cell. 1997;88(3):405–415. doi:10.1016/S0092-8674(00)81879-69039267
   PubMed Web of Science ®Google Scholar
• Sherr CJ, Beach D, Shapiro GI. Targeting CDK4 and CDK6: from discovery to therapy. Cancer Discov. 2016;6(4):353–367. doi:10.1158/2159-8290.CD-15-089426658964
   PubMed Web of Science ®Google Scholar
• Wang Z, Li B, Zhou L, et al. Prodigiosin inhibits Wnt/beta-catenin signaling and exerts anticancer activity in breast cancer cells. Proc Natl Acad Sci U S A. 2016;113(46):13150–13155. doi:10.1073/pnas.161633611327799526
   PubMed Web of Science ®Google Scholar
• Wang J, Li M, Chen D, et al. Expression of C-myc and beta-catenin and their correlation in triple negative breast cancer. Minerva Med. 2017;108(6):513–517. doi:10.23736/S0026-4806.17.05213-228889723
   PubMed Web of Science ®Google Scholar
• Chen Y, Li Y, Xue J, et al. Wnt-induced deubiquitination FoxM1 ensures nucleus beta-catenin transactivation. EMBO J. 2016;35(6):668–684. doi:10.15252/embj.20159281026912724
   PubMed Web of Science ®Google Scholar
• Shtutman M, Zhurinsky J, Simcha I, et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A. 1999;96(10):5522–5527. doi:10.1073/pnas.96.10.552210318916
   PubMed Web of Science ®Google Scholar
• Yang X, Du X, Sun L, et al. SULT2B1b promotes epithelial-mesenchymal transition through activation of the beta-catenin/MMP7 pathway in hepatocytes. Biochem Biophys Res Commun. 2019;510(4):495–500. doi:10.1016/j.bbrc.2019.01.03430658852
   PubMed Web of Science ®Google Scholar
• Xu J, Chen Y, Huo D, et al. Beta-catenin regulates c-Myc and CDKN1A expression in breast cancer cells. Mol Carcinog. 2016;55(5):431–439. doi:10.1002/mc.2229225663530
   PubMed Web of Science ®Google Scholar
• Chen HJ, Hsu LS, Shia YT, Lin MW, Lin CM. The beta-catenin/TCF complex as a novel target of resveratrol in the Wnt/beta-catenin signaling pathway. Biochem Pharmacol. 2012;84(9):1143–1153. doi:10.1016/j.bcp.2012.08.01122935447
   PubMed Web of Science ®Google Scholar
• Jho EH, Zhang T, Domon C, Joo CK, Freund JN, Costantini F. Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol. 2002;22(4):1172–1183. doi:10.1128/MCB.22.4.1172-1183.200211809808
   PubMed Web of Science ®Google Scholar